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FIGURE 2. Intraoperative photograph of the left atrial disk of the septal
occluder device (arrows) as it protrudes through the dome of the left atrium.
Brief Technique ReportsThe risk of erosion into the aorta has prompted
recommendation against device oversizing and straddling
over the aortic root.2 This recommendation has since been
disputed by expert opinion regarding the mechanism of
device-related erosions.3 Thus, opinions of some experienced
operators concerning erosions by the Amplatzer septal oc-
cluder have been at odds with manufacturer recommenda-
tions.4 This reported left atrial wall erosion may have
resulted from migration of the device through the superior
rim of the atrial septum and through the dome of the left
atrium. This speculation raises questions of unique individual
susceptibility to device erosion through the atrial wall.COMMEN
From Pediatric Cardiac Surgery,a C.S. Mott Children’s Hospital, University of
Michigan Medical School, Ann Arbor, Mich; and Cardiovascular Surgery,b
Children’s Hospital Boston, Harvard Medical School, Boston, Mass.
Address for reprints: Daniel J. DiBardino, MD, Cardiac Surgery, 5144 CVC/SPC
5864, 1500 East Medical Center Dr, Ann Arbor, MI 48109-5864 (E-mail:
Daniel.DiBardino@gmail.com).
J Thorac Cardiovasc Surg 2011;142:222-3
0022-5223/$36.00
Copyright  2011 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2011.04.014
222 The Journal of Thoracic and Cardiovascular SurgMost reported cases of erosion occur within 72 hours of
device placement.1,2 The latest reported erosion after PFO
closure occurred 16 months after device placement.5
Erosion after ASD closure has been documented 3 years
after device placement.2
We present the latest known case of device erosion after
placement of a relatively small (14 mm) Amplatzer septal
occluder device, 6 years after placement. This case illus-
trates the importance of recognizing the ongoing, albeit
low, risk of device erosion long after initial ASD/PFO clo-
sure. A history of ASD/PFO device closure should prompt
appropriate investigation in patients who have chest pain,
shortness of breath, new-onset heart failure symptoms, or
other symptoms suggestive of a cardiac etiology.References
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Thorac Surg. 2006;81:e29-30.TARYContinued controversy regarding adverse events after Amplatzer septal
device closure: Mass hysteria or tip of the iceberg?Daniel J. DiBardino, MD,a and John E. Mayer, Jr, MDbIn this issue of the Journal, Taggart and coauthors1 have re-
ported their experiencewith late erosion of anAmplatzer sep-
tal occluder device (AGA Medical Corporation, Plymouth,Minn), resulting in cardiac tamponade and necessitating sub-
sequent emergency surgery.1 Findings at surgery were perfo-
ration of the left side of the disk through the dome of the left
atrium. This case report contains several interesting pieces of
history including arrhythmia 10 days after Amplatzer device
placement and chest pain 1 month before the patient’s subse-
quent presentation with tamponade. They point out that 6
years is longer than the hazard function for erosion is com-
monly thought to have still been in effect. The longest previ-
ously reported interval between insertion and erosion of an
Amplatzer devicewas 3 years. It seems that the complication
pattern of this device is still being defined.ery c July 2011
Brief Technique ReportsIn 2009, we2 published the results of an exhaustive re-
view of the Food and Drug Administration (FDA)Manufac-
turer and User Facility Device Experience (MAUDE)
database regarding the incidence of reported adverse events
after Amplatzer device placement. In this review, we found
an increasing number of events reported over a 5.5-year
period, equivalent estimated mortality for device placement
compared with Society of Thoracic Surgeons database
surgical closure data, and a much higher need for operation
and operative mortality per adverse event for device closure
compared with surgical closure. After publication of these
data, wewere contacted by representatives of AGAMedical
Association, and their concerns regarding possible interpre-
tations of our results led to a clarification letter in a subse-
quent issue.3 Since that time we have been also contacted
by the FDA, where an updated data mining project is sup-
posed to be ongoing to further observe the trends in reported
complications.
Although AGA Medical has made honest attempts at
good faith reporting of ongoing results, we continue to
believe that a mandatory user registry, identical to what
surgeons use for ventricular assist devices, would be useful.
The current case report indicates that the long-term compli-
cation profile of this device is still unknown. A closer look
at the present report also reveals other interesting points that
echo the MAUDE registry findings. The fact that the patient
presented with new-onset arrhythmia 10 days after device
placement is not insignificant inasmuch as arrhythmia was
listed as an independent complication of device placement
and also was found as a warning sign of device emboliza-
tion, particularly into the right ventricle.2 New-onset ar-
rhythmias in a patient with an Amplatzer device should
be taken seriously, including an urgent echocardiographic
assessment.From the Mount Sinai Medical Center, New York, NY.
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The Journal of Thoracic and CaThe development of chest pain 1 month before the tam-
ponade episode may also be of relevance. The actual mech-
anism of the erosion of this device has been hotly debated,
but it seems that a gradually progressing erosion process is
a real possibility despite the manufacturer’s recommenda-
tions. Taggart and associates1 point out that ‘‘most reported
cases occur within 72 hours of placement,’’ but our
MAUDE data show that 24 of 51 known perforations
occurred greater than 24 hours from placement, with 8
occurring at 1 to 6 months, 2 at 6 months to 1 year, and at
3 greater than 1 year. The sites of erosion included various
combinations of atrium and/or aorta in the FDA reports, and
the left atrium was the common site of atrial level perfora-
tion. Until the mechanism of erosion and its relationship to
sizing and time after placement is better understood, we
cannot speculate on individual patient susceptibility.
The increasing number of reported adverse events with
the Amplatzer device may simply reflect an increase in
the number of devices placed. It is also possible that the
known events are just the ‘‘tip of the iceberg’’ with a con-
stant hazard function for erosion that exists over the lifetime
of the patient. The only way to get real answers to these
important issues is to actively collect short-term outcome
data and to continue active surveillance of these devices.
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EXCOR ventricular assist device in small pediatric patientsKhanh Nguyen, MD, New York, NYThe Berlin Heart EXCOR (Berlin, Germany) ventricular as-
sist device has been used with increasing frequency in youn-
ger pediatric patients. The smallest available blood pump has
a 10-mL volume, and the smallest outflow cannula tip is 3
mm in diameter. The cannula has a 90-degree angulation
with a flanged tip for sewing to the ascending aorta or main
pulmonary artery. There is a short, grooved extension from
the flange in this design. During a typical cannula insertion,
a side-biting clamp is placed on the aorta and the cannula
is anastomosed to a matching arteriotomy while the patientrdiovascular Surgery c Volume 142, Number 1 223
